These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 7477400)

  • 1. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
    Yaneva R; Springer S; Zacharias M
    Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
    Verreck FA; Fargeas CA; Hämmerling GJ
    Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
    Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
    J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
    Xu M; Jackson R; Adams S; Humphreys RE
    Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
    Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
    J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel domain on HLA-DRbeta chain regulates the chaperone role of the invariant chain.
    Neumann J; Koch N
    J Cell Sci; 2006 Oct; 119(Pt 20):4207-14. PubMed ID: 16984974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-release of CLIP in peptide loading of HLA-DR molecules.
    Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
    Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
    van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
    Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.
    Nauss JL; Reid RH; Sadegh-Nasseri S
    J Biomol Struct Dyn; 1995 Jun; 12(6):1213-33. PubMed ID: 7669268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.